VALLARIS™ measures the fair value of convertible notes, preference shares, warrants and options, earn-outs and contingent consideration, loans and guarantees, for financial reporting, deals and disputes.
Financial instrument valuation measures the fair value of instruments that have no quoted price, such as convertible notes, preference shares, warrants, earn-outs and intercompany loans. It is required under IFRS 9 and IFRS 13 (SFRS(I) 9 and SFRS(I) 13 in Singapore), and uses option pricing, binomial lattice and Monte Carlo models chosen to match each instrument’s terms.
The auditor wants support for the fair value of a Level 3 instrument. You want it before the field work starts.
A convertible, a preference share or a warrant needs to be split and measured on day one.
Contingent consideration has to be measured at acquisition and at every reporting date after.
I sit on the working group of the Institute of Valuers and Appraisers, Singapore that writes the country’s valuation standards. I build instrument valuations to be read by an auditor, line by line.
Siong Yoong
About VALLARIS™ →
CVA, Institute of Valuers and Appraisers, Singapore (IVAS).
Member since 2018 of the IVAS Standards & Technical Working Group, which writes Singapore’s business valuation standards.
Member, Memberships & Standards Recognition Committee, IVSC, the body that publishes the IVS.
Six questions. Your score and focus areas appear as you answer. No email needed.
0 of 6 answered.
Thirty minutes, confidential, and no fee for the first conversation.
A Level 3 fair value relies on significant inputs that cannot be observed in a market, such as a private company’s expected volatility or cash flows. IFRS 13 requires more disclosure for Level 3 measurements, including sensitivity to the key inputs.
A convertible note is valued by separating the debt and the conversion option, or by valuing the whole instrument with a lattice or Monte Carlo model that captures the conversion, redemption and any discount or cap terms.
An embedded derivative is a feature within a contract, such as a conversion right or an index-linked payment, that changes the contract’s cash flows like a derivative. Under IFRS 9 some must be separated and measured at fair value.
Instruments measured at fair value through profit or loss must be valued at each reporting date, so usually at every half-year and year-end.
No. SFRS(I) 9 and SFRS(I) 13 are identical to IFRS 9 and IFRS 13, so a valuation prepared under one meets the other.
Share-based payment valuation measures the fair value of equity awards given to employees and others, such as share options, restricted shares and performance shares, at the grant date.
Portfolio company valuation sets the fair value of a fund’s unlisted investments at each reporting date, as required by IFRS 13 and set out in the IPEV Valuation Guidelines.
Purchase price allocation (PPA) splits the price paid for an acquired business across its identifiable assets and liabilities at fair value, including intangible assets such as customer relationships, brands and technology.